Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MCRB
stocks logo

MCRB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-2.170
-1.36%
--
--
-1.995
-153.2%
--
--
-2.065
-9.03%
Estimates Revision
The market is revising Downward the revenue expectations for Seres Therapeutics, Inc. (MCRB) for FY2025, with the revenue forecasts being adjusted by -98.3% over the past three months. During the same period, the stock price has changed by -7.54%.
Revenue Estimates for FY2025
Revise Downward
down Image
-98.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-186.77%
In Past 3 Month
Stock Price
Go Down
down Image
-7.54%
In Past 3 Month
Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.900
sliders
Low
22.00
Averages
22.00
High
22.00
Current: 17.900
sliders
Low
22.00
Averages
22.00
High
22.00
Canaccord
Buy
maintain
$14 -> $22
2025-09-24
Reason
Canaccord
Price Target
$14 -> $22
2025-09-24
maintain
Buy
Reason
Canaccord raised the firm's price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres' proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.
Chardan
Buy -> Neutral
downgrade
$6
2025-05-08
Reason
Chardan
Price Target
$6
2025-05-08
downgrade
Buy -> Neutral
Reason
Chardan downgraded Seres Therapeutics to Neutral from Buy with a $6 price target.
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$1.25
2025-03-20
Reason
Chardan Capital
Keay Nakae
Price Target
$1.25
2025-03-20
Maintains
Strong Buy
Reason
Goldman Sachs
Chris Shibutani
Strong Sell
Maintains
$1 → $0.75
2025-03-14
Reason
Goldman Sachs
Chris Shibutani
Price Target
$1 → $0.75
2025-03-14
Maintains
Strong Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Seres Therapeutics Inc (MCRB.O) is -2.16, compared to its 5-year average forward P/E of -5.89. For a more detailed relative valuation and DCF analysis to assess Seres Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.89
Current PE
-2.16
Overvalued PE
8.95
Undervalued PE
-20.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
13.13
Undervalued EV/EBITDA
-25.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
20.34
Current PS
0.00
Overvalued PS
41.46
Undervalued PS
-0.77
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MCRB News & Events

Events Timeline

(ET)
2025-11-05
07:03:11
Seres Therapeutics announces Q3 EPS of 94 cents compared to a loss of $6.69 in the previous year.
select
2025-10-29 (ET)
2025-10-29
07:16:21
Seres Therapeutics awarded up to $3.6M by CARB-X
select
2025-09-23 (ET)
2025-09-23
07:03:38
Seres Therapeutics Receives Additional Positive Feedback from FDA Regarding SER-155
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-06NASDAQ.COM
Seres (MCRB) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.0
09-23NASDAQ.COM
Seres Receives Positive Input from FDA on Phase 2 Study Protocol for SER-155; Plans Workforce Reduction

  • FDA Feedback on SER-155: Seres Therapeutics received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in adults undergoing stem cell transplants, which will aid in finalizing the protocol.

  • Workforce Reduction and Financial Outlook: The company is reducing its workforce by approximately 25%, which is expected to incur cash payments of $1.0 - $1.4 million in Q4 2025, while extending its cash runway into the second quarter of 2026.

[object Object]
Preview
5.0
09-23SeekingAlpha
Seres Therapeutics reduces workforce by 25% to prolong cash reserves until Q2 2026.

  • Cost-Cutting Measures: Seres Therapeutics plans to reduce its workforce by about 25% to trim operating costs, which is expected to extend its cash runway into the second quarter of 2026.

  • SER-155 Study Development: Following positive FDA feedback, the company aims to finalize the Phase 2 study protocol for SER-155, targeting bloodstream infections in adults undergoing stem cell transplants, while seeking capital to support this and other biotherapeutic developments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Seres Therapeutics Inc (MCRB) stock price today?

The current price of MCRB is 17.9 USD — it has increased 2.64 % in the last trading day.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s business?

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

arrow icon

What is the price predicton of MCRB Stock?

Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s revenue for the last quarter?

Seres Therapeutics Inc revenue for the last quarter amounts to 351.00K USD, decreased % YoY.

arrow icon

What is Seres Therapeutics Inc (MCRB)'s earnings per share (EPS) for the last quarter?

Seres Therapeutics Inc. EPS for the last quarter amounts to 0.94 USD, decreased -91.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Seres Therapeutics Inc (MCRB)'s fundamentals?

The market is revising Downward the revenue expectations for Seres Therapeutics, Inc. (MCRB) for FY2025, with the revenue forecasts being adjusted by -98.3% over the past three months. During the same period, the stock price has changed by -7.54%.
arrow icon

How many employees does Seres Therapeutics Inc (MCRB). have?

Seres Therapeutics Inc (MCRB) has 103 emplpoyees as of December 05 2025.

arrow icon

What is Seres Therapeutics Inc (MCRB) market cap?

Today MCRB has the market capitalization of 161.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free